Neurizon Therapeutics Ltd (NUZ)

Sydney
Currency in AUD
0.180
+0.005(+2.86%)
Delayed Data·
NUZ Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NUZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1700.180
52 wk Range
0.0960.245
Key Statistics
Edit
Bid/Ask
0.17 / 0.18
Prev. Close
0.175
Open
0.17
Day's Range
0.17-0.18
52 wk Range
0.096-0.245
Volume
43.65K
Average Volume (3m)
331.65K
1-Year Change
-14.63%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NUZ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.420
Upside
+133.33%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Neurizon Therapeutics Ltd News & Analysis

Show more

Neurizon Therapeutics Ltd Company Profile

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Employees
4
Market
Australia

Compare NUZ to Peers and Sector

Metrics to compare
NUZ
Peers
Sector
Relationship
P/E Ratio
−5.9x−8.2x−0.5x
PEG Ratio
0.09−0.020.00
Price/Book
7.2x3.9x2.6x
Price / LTM Sales
56.8x9.7x3.0x
Upside (Analyst Target)
140.0%243.8%52.4%
Fair Value Upside
Unlock14.5%8.7%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.420
(+133.33% Upside)

Earnings

Latest Release
Feb 17, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
1.53M / --
EPS Revisions
Last 90 days

NUZ Income Statement

FAQ

What Is the Neurizon Therapeutics (NUZ) Stock Price Today?

The Neurizon Therapeutics stock price today is 0.18

What Stock Exchange Does Neurizon Therapeutics Trade On?

Neurizon Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Neurizon Therapeutics?

The stock symbol for Neurizon Therapeutics is "NUZ."

What Is the Neurizon Therapeutics Market Cap?

As of today, Neurizon Therapeutics market cap is 86.15M.

What Is Neurizon Therapeutics's Earnings Per Share (TTM)?

The Neurizon Therapeutics EPS (TTM) is -0.03.

From a Technical Analysis Perspective, Is NUZ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Neurizon Therapeutics Stock Split?

Neurizon Therapeutics has split 6 times.

How Many Employees Does Neurizon Therapeutics Have?

Neurizon Therapeutics has 4 employees.

What is the current trading status of Neurizon Therapeutics (NUZ)?

As of 22 June 2025, Neurizon Therapeutics (NUZ) is trading at a price of 0.18, with a previous close of 0.18. The stock has fluctuated within a day range of 0.17 to 0.18, while its 52-week range spans from 0.10 to 0.25.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.